COVID-19

Read more about IIT Guwahati develops affordable diagnostic kits for COVID-19

Accurate testing is important to get out of the clutches of novel coronavirus. Steeping up efforts in this regard, the Indian Institute of Technology (IIT) Guwahati, in association with RR Animal Healthcare Ltd and Guwahati Medical College and Hospital (GMCH), has developed low-cost diagnostic kits. These are Viral Transport Media (VTM) kits, RT-PCR kits, and RNA isolation kits. Himanta Biswa Sarma, the Minister of Finance, Health and Family Welfare, Assam, launched the VTM kits.

Read more about CDRI to carry Phase III clinical trials of Umifenovir

The Central Drug Research Institute (CDRI), Lucknow, has received permission from Drug Controller General of India (DCGI) for carrying out Phase III clinical trials to test the efficacy, safety and tolerability of the antiviral drug Umifenovir. The Phase III activities will be carried out at King George's Medical University (KGMU), Dr Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA's Lucknow Medical College and Hospital, Lucknow.

Read more about The Lancet Infectious Diseases: Study from Chinese city of Guangzhou provides key insights on how COVID-19 spreads in households

New modelling research, published in The Lancet Infectious Diseases journal, suggests the coronavirus (SARS-CoV-2) that causes COVID-19 may spread more easily among people living together and family members than severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS). The estimates are the first of their kind to quantify symptomless transmission.

Read more about Breakthrough in COVID-19 treatment with Dexamethasone

The NIHR-funded and supported study RECOVERY (Randomised Evaluation of COVid-19 thERapY) has today announced that the steroid dexamethasone has been identified as the first drug to improve survival rates in certain coronavirus patients.

Read more about Dr. Reddy's Lab wins right to sell Gilead’s Remdesivir in 127 countries including India

Dr. Reddy's Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Read more about Johnson & Johnson to begin Phase 1/2a Clinical Trials of COVID-19 vaccine in July

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.

10 June 2020

COVID – 19 DIAGNOSIS : A SHORT REVIEW

ABOUT AUTHORS
Swarupananda Mukherjee*, Sohini Bera, Moumoyee Chakraborty
NSHM Knowledge Campus, Kolkata – Group of Institutions,
Department of Pharmaceutical Technology, 124, B L Saha Road,
Kolkata, India
* Swarupananda.mukherjee@nshm.com

ABSTRACT :
Corona viruses are a family of enveloped, positive stranded, single stranded RNA viruses. This corona virus family consists of pathogens of several human and animal species including SARS-CoV, NovelCOVID-19 but now referred to as SARS-CoV-2 by the Study Group. SARS-CoV-2 International Committee on Virus Taxonomy Corona Virus belongs to the genus Beta corona virus family Corona viridae. The virus has spread globally since its introduction, causing millions of deaths and critically affecting our health services and economies. There are currently no approved preventive drugs or treatment methods available. Hundreds of clinical trials were performed to find treatments that were successful. Here we are reviewing currently reported clinical studies for COVID-19 treatment and prevention to give an overview and perspective into the global response.

Read more about Gilead Sciences Tests Remdesivir in Patients with Moderate COVID-19 as a Part of Its Phase 3 Trials

Gilead Sciences, Inc announced that it conducted phase 3 trials for the antiviral drug remdesivir in patients with moderate COVID-19 pneumonia who were admitted to hospitals.

4 June 2020

Corona virus disease-2019 (COVID-19) : The epidemic and the challenges

ABOUT AUTHORS :
Disha Chouhana*1, Dr. Rajesh Mujariya2
1*Department of Pharmaceutical Chemistry, School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India
2Department of Pharmaceutics, School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India
rajeshmujariya@gmail.com

ABSTRACT :
There is a new public health crises threatening the world with the emergence and spread of 2019 novel corona virus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of corona virus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d.

4 June 2020

Five tips on how to live with novel coronavirus

After seventy days of lockdown, the unlock 1.0 is put into action. Officially designated lockdown 5.0, from June 1, 2020, the economy and ordinary life are returning to normalcy in a controlled and phased manner. This is the beginning of a new normal. It is going to be a long haul. Experts and officials are suggesting that ‘we must learn to live with the virus’. With vaccine still months away, we need to live in a new normal. Speaking to India Science Wire, Prof. K Vijay Raghavan, Principal Scientific Advisor to the Government of India, gave five tips to ‘living with the virus’.

Search

RECOMMENDED POSTS

Subscribe with us

Jobs by Category